Form 4: Neurocrine Legal Officer's Routine Stock Transactions

Neurocrine Biosciences' Chief Legal Officer, Darin Lippoldt, reported the vesting of restricted stock units and subsequent tax-related share withholding.

Summary

• Darin Lippoldt, Chief Legal Officer of Neurocrine Biosciences Inc. (NBIX), reported transactions involving the company's common stock.
• On January 31, 2026, 2,373 shares of common stock were acquired through the exercise/conversion of restricted stock units (RSUs) at a price of $0.
• Concurrently, 1,335 shares of common stock were disposed of at a price of $136.06 to satisfy tax withholding requirements related to the RSU vesting.
• Following these transactions, Darin Lippoldt beneficially owns 47,792 shares of Neurocrine Biosciences common stock directly.
• The RSUs were granted on January 31, 2022, and vested in equal installments of 2,373 shares on January 31 of 2023, 2024, 2025, and 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. It represents routine executive compensation through RSU vesting, which is a positive for management alignment, but the tax-related share withholding is a standard, non-discretionary event.

Positives

• The vesting of 2,373 restricted stock units represents a scheduled compensation event for the Chief Legal Officer, indicating continued alignment of management interests with shareholder value.
• The acquisition of shares at a $0 price reflects the successful vesting of previously granted equity awards.

Negatives

• 1,335 shares were withheld by the company to cover tax obligations, resulting in a reduction of the direct beneficial ownership of common stock.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to the vesting of restricted stock units and subsequent tax withholding, are common occurrences in publicly traded companies. These events are typically part of pre-established executive compensation plans and do not usually signal a change in strategic direction or financial health. They reflect routine compensation mechanisms designed to align executive incentives with long-term company performance.

Stakeholder Impact

• Shareholders: The transaction is a routine compensation event and does not indicate any significant change in company strategy or financial performance. It reflects the ongoing alignment of executive incentives with company performance.
• Employees: No direct impact on general employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to the vesting of restricted stock units and subsequent tax withholding. Such events are part of standard executive compensation and do not provide new fundamental information that would warrant a change in investment recommendation. The transactions are expected and do not signal any material shift in the company's outlook or valuation.

Keywords

NBIX, Neurocrine Biosciences, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Darin Lippoldt, Equity Compensation, Stock Vesting